赵鑫 郑占杰

【摘 要】目的：探究卒中后焦虑伴睡眠障碍患者给予右佐匹克隆联合黛力新治疗方案对临床治疗效果的影响。方法：将2017年11月到2019年12月在本院接受治疗的80例卒中后焦虑伴睡眠障碍患者，随机分为两组，观察组40例，对照组40例，对照组给予黛力新治疗方案，观察组给予黛力新联合右佐匹克隆治疗，将两组抑郁情况和失眠情况进行记录和对比。结果：观察组轻度抑郁率为75.00%高于对照组（P<0.05）;观察组重度抑郁率为2.50%显著低于对照组（P<0.05）;观察组轻度失眠率为65.00%高于对照组（P<0.05），观察组重度失眠率为5.00%显著低于对照组，差异具统计学意义（P<0.05）。结论：卒中后焦虑伴睡眠障碍患者给予右佐匹克隆联合黛力新治疗方案能够显著提升患者睡眠质量，有效缓解患者不良情绪，具一定临床应用价值。

【关键词】黛力新;右佐匹克隆;卒中;焦虑伴睡眠障碍;疗效

Abstract：Objective To explore the effect of dexazopiclone combined with Dalixin on patients with anxiety and sleep disorders after stroke. Methods： 80 patients with post-stroke anxiety and sleep disorders who were treated in our hospital from November 2017 to December 2019 were randomly divided into two groups， 40 in the observation group， 40 in the control group， and Dai Lixin in the control group. In the treatment plan， the observation group was given Dailixin combined with eszopiclone， and the depression and insomnia of the two groups were recorded and compared. Results： The mild depression rate in the observation group was 75.00% higher than the control group （P <0.05）; the severe depression rate in the observation group was 2.50% significantly lower than the control group （P <0.05）; the mild insomnia rate in the observation group was 65.00% higher In the control group （P <0.05）， the severe insomnia rate in the observation group was 5.00%， which was significantly lower than that in the control group， and the difference was statistically significant （P <0.05）. Conclusion： Patients with anxiety and sleep disorders after stroke can be treated with dexazopiclone combined with Dalixin treatment， which can significantly improve the sleep quality of patients， effectively alleviate the adverse emotions of patients， and have certain clinical application value.

Key words： Dai Lixin; eszopiclone; stroke; anxiety with sleep disturbance; efficacy

脑卒中是一种高发病率、死亡率的中老年疾病，睡眠障碍是临床常见症状[1]。患者因无力、无法与外界沟通易出现抑郁等负面情绪，且不良情绪会导致患者出现失眠、多梦、早醒等情况发生，严重威胁患者身心健康[2-3]。

本文探究2017年11月到2019年12月本院卒中后焦虑伴睡眠障碍患者给予黛力新联合右佐匹克隆治疗方案的临床效果影响分析，报道如下。

1 资料与方法

1.1 一般资料

选取2017年11月到2019年12月在本院接受治疗的80例卒中后焦虑伴睡眠障碍患者，研究符合医学伦理会批准，患者签署知情同意书排除标准：资料不完整者，其他精神心理障碍疾病者，肝肾功能障碍者，该方案用药禁忌者;随机分为两组，每组40例，观察组男性30例、女性10例，年龄区间为50～78岁，平均（59.87±9.27）岁;对照组男性30例、女性10例年龄区间为52～76岁，平均（54.23±9.59）岁。两组患者年龄等基本资料无明显差异（P>0.05）。

1.2 方法

对照组给予黛力新治疗（生产厂家：丹麦灵北制药有限公司 标准：JX19980123）方案，每天两次，早晚各一片，两周为一治疗周期。